Viromed Medical AGXTER:VME -2.04%15 ROE % is 11.44% as of Dec. 2025. GuruFocus rates XTER:VME with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Viromed Medical AG ranks better than 56.95% on this metric.
The historical rank and industry rank for Viromed Medical AG's ROE % or its related term are showing as below:
XTER:VME'
s ROE % Range Over the Past 10 Years
Min: -21.15 Med: -1.58 Max: 6.13
Current: 4.51
During the past 5 years, Viromed Medical AG's highest ROE % was 6.13%. The lowest was -21.15%. And the median was -1.58%.
XTER:VME's ROE % is ranked better than 56.95% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs XTER:VME: 4.51
Viromed Medical AG (XTER:VME) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Viromed Medical AG ROE % Related Terms
Viromed Medical AG ROE % Historical Data
* Premium members only.
The historical data trend for Viromed Medical AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Viromed Medical AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viromed Medical AG ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's ROE % distribution charts can be found below:
* The bar in red indicates where Viromed Medical AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Viromed Medical AG (XTER:VME) has a ROE % of 11.44% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Viromed Medical AG and its competitors. According to the industry distribution chart, Viromed Medical AG ranks #344 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 43.1%.
Is Viromed Medical AG's ROE % too high?
Viromed Medical AG's current ROE % is 11.44%. The Medical Devices & Instruments industry median ROE % is 2.42. Viromed Medical AG's value of 11.44% is 372.7% above this industry median. Based on the distribution chart, Viromed Medical AG ranks #344 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Viromed Medical AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Viromed Medical AG ranks #344 out of 799 companies for ROE %. This puts Viromed Medical AG in the upper half of its industry. The industry median ROE % is 2.42. Viromed Medical AG's value of 11.44% is 372.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viromed Medical AG's current ROE % of 11.44% is 372.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Viromed Medical AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viromed Medical AG's current ROE % is 11.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (XTER:VME) has a current ROE % of 11.44%. The current ROE % is 11.44% and 372.7% above the Medical Devices & Instruments industry median of 2.42. Viromed Medical AG's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Viromed Medical AG (XTER:VME), the current ROE % is 11.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
15GF Score
Get the complete analysis for XTER:VME
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:VME has been successfully added to your 
